For the year ending 2025-12-31, ALLR had -$4,180K decrease in cash & cash equivalents over the period. -$14,828K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -11,231 |
| Depreciation and amortization | -13 |
| Intangible asset impairment | 0 |
| Common stock issued for services | -200 |
| Stock-based compensation expense | 482 |
| Unrealized foreign exchange gain | -1,238 |
| Non-cash interest expense | 185 |
| Change in fair value of warrant derivative liabilities | -1 |
| Deferred income taxes | 0 |
| Other current assets | 150 |
| Unearned revenue | 0 |
| Tax credit receivable | 96 |
| Prepaid expenses | 1,603 |
| Accounts payable | -1,139 |
| Accrued liabilities | -2,699 |
| Income taxes payable | 7 |
| Net cash used in operating activities | -14,820 |
| Purchase of property and equipment | 8 |
| Net cash used in investing activities | -8 |
| Proceeds from 3i promissory notes | 0 |
| Repayment of 3i debt | 0 |
| Proceeds from atm sales of common stock, net of issuance costs | 11,143 |
| Net proceeds from common stock and pre-funded warrant issuance | 2,695 |
| Proceeds from issuance of convertible redeemable series a preferred stock | 0 |
| Redemption of convertible redeemable series a preferred stock | 0 |
| Common stock repurchase | 3,190 |
| Net cash provided by financing activities | 10,648 |
| Net increase (decrease) in cash | -4,180 |
| Cash, beginning of year | 19,533 |
| Cash, end of year | 14,687 |
Allarity Therapeutics, Inc. (ALLR)
Allarity Therapeutics, Inc. (ALLR)